இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ் Today - Breaking & Trending Today

Gedeon Richter: Cariprazine is well tolerated in the early stage of schizophrenia and has a positive effect on engagement compared to another antipsychotic

Gedeon Richter: Cariprazine is well tolerated in the early stage of schizophrenia and has a positive effect on engagement compared to another antipsychotic
Between the 10-13
was held virtually due to the COVID-19 pandemic situation -
new analysis of cariprazine studies with patients experiencing acute or predominant negative symptoms (PNS) of schizophrenia was presented by Gedeon Richter Plc. According to the scientific posters, cariprazine significantly improved patient engagement in individuals suffering from PNS compared to risperidone, and the co-administration of cariprazine with other antipsychotic medications did not show an unexpected safety profile nor overlapping toxicities. It was also shown that cariprazine was well-tolerated in the early stage of the illness (first five years) and the discontinuation rates due to unbearable side effects were also low. ....

United States , Italian Stock Exchange Reuters , Meeting Of The European Psychiatric Association , Gedeon Richter Plc , Gedeon Richter , Annual Meeting , European Psychiatric Association , Negative Syndrome Scale , Brand Name , Recordati Spa , Western European , Central Eastern Europe , Western Europe , Central Nervous System , Italian Stock Exchange , North Africa , South American , ஒன்றுபட்டது மாநிலங்களில் , இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ் , சந்தித்தல் ஆஃப் தி ஐரோப்பிய மனநல சங்கம் , கேதெோன் பணக்காரர் ப்ல் , கேதெோன் பணக்காரர் , ஆண்டு சந்தித்தல் , ஐரோப்பிய மனநல சங்கம் , எதிர்மறை நோய்க்குறி அளவு , பிராண்ட் பெயர் ,

RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE ...

RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , J Clin Endocrinol , Clin Endocrinol , Andrea Recordati , Noris Morano , Italian Stock Exchange Reuters , Recordati Rare Diseases Inc , Endocrine Society Annual Meeting , Recordati Group , Recordati Rare Diseases , Endocrine Society , Universidade Federal , Annual Meeting , Pract Res Clin Endocrinol Metab , Rare Diseases , Italian Stock Exchange , North Africa , South American , Media Relations , Studio Noris Morano , ஒன்றுபட்டது மாநிலங்களில் , இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ் , நாளமில்லா சமூகம் ஆண்டு சந்தித்தல் , நாளமில்லா சமூகம் , யுனிவர்சிடேட் கூட்டாட்சியின் , ஆண்டு சந்தித்தல் ,

RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.

RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New York , United States , United Kingdom , City Of , Andrea Recordati , Noris Morano , Italian Stock Exchange Reuters , Tolmar International Ltd , Investors Company Presentations , Recordati Group , Luigi La Corte , Consolidated Law , Italian Stock Exchange , North Africa , South American , Private Securities Litigation Reform Act , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ் , முதலீட்டாளர்கள் நிறுவனம் ப்ரெஸெஂடேஶந்ஸ் , லூயிஜி லா கோர்டே , தொகுக்கப்பட்டு சட்டம் , இத்தாலிய ஸ்டாக் பரிமாற்றம் , தெற்கு அமெரிக்கன் ,

Investegate |RECORDATI Announcements | RECORDATI: RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES

RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES

Milan, 29 January 2021 – Recordati announces the closing of a License and Supply Agreement with Tolmar International Ltd, to commercialise Eligard® (leuprorelin acetate), in Europe, Turkey, Russia and other countries. Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
The active ingredient of Eligard® is leuprorelin acetate, a powder which is solubilized with a solvent for subcutaneous injection. Eligard® is available in three different dosages (for 1-month, 3-month and 6-month treatment, respectively) as a single kit containing two syringes. The development of a new device to admin ....

United States , Andrea Recordati , Noris Morano , Italian Stock Exchange Reuters , Astellas Pharma Inc , Tolmar International Ltd , Tolmar International , Supply Agreement , Italian Stock Exchange , North Africa , South American , Studio Noris Morano , ஒன்றுபட்டது மாநிலங்களில் , இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ் , இத்தாலிய ஸ்டாக் பரிமாற்றம் , தெற்கு அமெரிக்கன் ,

RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES

Milan, 29 January 2021 – Recordati announces the closing of a License and Supply Agreement with Tolmar International Ltd, to commercialise Eligard® (leuprorelin acetate), in Europe, Turkey, Russia and other countries. Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
The active ingredient of Eligard® is leuprorelin acetate, a powder which is solubilized with a solvent for subcutaneous injection. Eligard® is available in three different dosages (for 1-month, 3-month and 6-month treatment, respectively) as a single kit containing two syringes. The development of a new device to administer the product which is easier to handle is currently ongoing, following the request from EMA. The regulatory variation is expected to be submitted by 31 October 2021. ....

United States , Andrea Recordati , Noris Morano , Italian Stock Exchange Reuters , Astellas Pharma Inc , Tolmar International Ltd , Tolmar International , Supply Agreement , Italian Stock Exchange , North Africa , South American , Studio Noris Morano , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , இத்தாலிய ஸ்டாக் பரிமாற்றம் ராய்ட்டர்ஸ் , இத்தாலிய ஸ்டாக் பரிமாற்றம் , தெற்கு அமெரிக்கன் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,